Genetic Testing for the Diagnosis of Essential Thrombocythemia (ET)



Focus of Report
This report evaluates the clinical utility of genotyping of calreticulin (CALR), Janus kinase 2 (JAK2), and thrombopoietin receptor (MPL) gene variants to improve the diagnosis of patients suspected of essential thrombocythemia (ET).

Health Problem
ET is one of several classic myeloproliferative neoplasms (MPNs). MPNs are hematological diseases that are characterized by the overproduction of mature blood cells (Campbell and Green, 2006). MPNs include chronic myeloid leukemia (CML), polycythemia vera (PV), ET, and primary myelofibrosis (PMF) (Tefferi and Vardiman, 2008). CML is defined by the presence of the breakpoint cluster region-Abelson (BCR-ABL) (Philadelphia chromosome fusion gene) (Tefferi and Vardiman, 2008). PV, ET, and PMF are all BCR-ABL chromosome negative and constitute the BCR-ABL–negative MPNs (Tefferi and Vardiman, 2008; Tefferi, 2014a). This report focuses on ET but first introduces general information pertinent to the BCR-ABL–negative MPNs before specifically addressing ET.

Download the report to continue reading…

  • *denotes required field
Privacy Policy
We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand where our visitors are coming from. By browsing our website, you consent to our use of cookies and other tracking technologies.
Thanks for signing up. You must confirm your email address before we can send you. Please check your email and follow the instructions.